



ASX Release

30 May 2016

New UK Guidelines Recommend use of FerriScan® R2-MRI in Haemoglobin Disorders

The 42nd Academic Meeting of the UK Forum on Haemoglobin Disorders in association with the UK Thalassaemia Society has launched a new set of guidelines; **UK Standards of Care for Thalassaemia**.

The recommendations for monitoring and management of iron overload state:

'Liver Iron Concentration LIC should be assessed using a validated and standardised MR technique. R2 (FerriScan) is preferable to R2 because the methodology is more robustly standardised and has been licensed for use in routine clinical practice.'*

'MRI LIC methods should not be used interchangeably. In particular, sequential MRI estimations in an individual patient should be done with the same methodology.'

Furthermore, the suggested lower age limit for commencement of monitoring of liver and cardiac iron has been lowered to seven years. FerriScan R2 is suitable for paediatric patients as it requires no breath hold.

'LIC and Myocardial iron should be monitored regularly in patients from age 7 or younger if able to tolerate MRI scanning without sedation.'

The availability of T2* / R2* methodologies for liver iron measurement was noted but as the calibrations of these methods varied, and consensus had not yet been reached on their standardisation, FerriScan R2 was the recommended technique.

To view a list of the patient management guidelines recommending FerriScan please [click here](#).

Professor Tim St Pierre, Chief Scientific Officer of Resonance Health, provider of the FerriScan service said:

"The continual clinical education and proactive stakeholder work we undertake to profile data on the accuracy of FerriScan is vital to obtain inclusion in Guidelines such as this. FerriScan has become the Gold Standard for measurement of liver iron concentration in haemoglobin disorders. The UK Standards of Care further substantiate the position of FerriScan as the only method that offers the standardisation that is a prerequisite for reliable measurements on which to base patient treatment decisions. There is no substitute for accuracy."

Melanie Baxter, UK-based Marketing Director for Resonance Health said;

“This further recognition of FerriScan as the preferred technique is expected to facilitate increased uptake by clinicians in the UK along with better NHS funding pathways for FerriScan. The recognition also assists our efforts to work towards reimbursement in other regions as healthcare standards in the UK are held in high regard.

We will now leverage the new UK Standards of Care in our global marketing efforts to increase FerriScan use, raise awareness of the limitations of competitive products, empower patients to request optimum care and support the growth of our clinical network.”

Over 30,000 patient FerriScans have now been performed in more than 30 countries worldwide.

For further information contact:

Sander Bangma

General Manager, Resonance Health

E: SanderB@resonancehealth.com P: +61 (0)8 92845300